Bristol Myers Squibb said on 12 October 2026 that its pivotal ALOFT-IPF trial of admilparant met its primary endpoint in idiopathic pulmonary fibrosis. Only the 60 mg dose beat placebo by a statistically significant margin.
The shares rose more than 6% before the opening bell, then reversed into a loss of roughly 4%. Contineum Therapeutics, which is testing a drug in the same LPA1 class, fell about 30% in morning trading, BioPharma Dive reported.
Investors read a split-dose result with no published effect size as a warning for the whole drug class. Detailed data are due at a future medical meeting the company has not named.
Only the 60 mg dose cleared the 52-week lung function test
The trial enrolled about 1,255 adults with IPF and randomized them evenly to 60 mg, 120 mg or placebo, the company’s announcement showed. Patients took their assigned dose twice daily for at least 52 weeks.
The primary endpoint was absolute change from baseline in forced vital capacity, the volume of air a person can forcefully exhale, at Week 52. At 60 mg, admilparant improved that measure significantly against placebo.
At 120 mg, the drug slowed lung function decline but missed statistical significance, the release disclosed. Discontinuations due to side effects stayed low in both drug arms and tracked close to placebo.
“Taken together, these topline data reinforce the profile of admilparant as a promising, clinically meaningful investigational therapy for IPF.” — Cristian Massacesi, MD, executive vice president, chief medical officer and head of development, Bristol Myers Squibb, in the company’s announcement
Massacesi framed the readout as confirmation of the drug’s profile, although the release put no number on the benefit at either dose.
Bristol Myers withheld the size of the benefit
The announcement disclosed no effect size, confidence interval or p-value for either dose. Detailed results will follow at a future medical meeting, with no venue or date named.
The company cited two efficacy figures from an earlier 26-week Phase 2 trial: a 62% relative reduction in the rate of lung function decline among patients with IPF and a 69% reduction among patients with PPF. Neither figure represents the Phase 3 ALOFT-IPF result, for which the company has not yet disclosed the size of the treatment benefit.
Bristol Myers said it will evaluate the full dataset and engage health authorities on planned submissions, without giving a filing date.
A regulatory decision would be its own catalyst, like the FDA clearance of Medtronic’s Hugo vessel sealer in September 2026.
Analysts split on what a weaker high dose signals
Drug reviewers typically expect a higher dose to perform at least as well as a lower one, BioPharma Dive noted. The 120 mg arm broke that pattern, and the stock reversal followed.
RBC Capital Markets analyst Trung Huynh described the high-dose miss as “confounding” in a client note and said it required further explanation, the trade outlet reported.
“The lack of dose response raises questions about [admilparant’s] profile.”
“We await detailed results to better understand the drug’s efficacy.” — David Risinger, analyst, Leerink Partners, in a client note reported by BioPharma Dive
Risinger said the data could be enough for approval, which moves the open question from the regulator to the drug’s commercial profile.
William Blair analyst Matt Phipps took the bullish side, writing that the lower dose’s success is “likely to open a blockbuster opportunity,” BioPharma Dive added.
More related news on FinanceTracked:
- Novo Nordisk stock falls as 2026 plan targets peer growth
- Beta Bionics cuts 2026 forecast by $10m after Mint nod
- J&J offloads $400M Laminar bet and exits LAA closure
Earlier LPA1 failures primed the sell-off
Admilparant is the most advanced LPA1 receptor antagonist, a class that blocks a signaling molecule tied to lung scarring, the outlet explained. Its predecessors fared poorly.
Bristol Myers dropped an earlier LPA1 candidate, BMS-986020, over liver toxicity, and Amgen ended its program after a Phase 2 shortfall, BioPharma Dive reported.
Concerns intensified in September 2026, when Bristol Myers revised safety monitoring at European sites in the admilparant trial’s long-term extension. BioPharma Dive reported a limited number of liver-related safety events, including a participant’s death involving liver injury.
The company had not established whether the participant received admilparant or whether the drug caused the death.
The October 12 Phase 3 announcement subsequently reported low rates of discontinuation due to adverse events, similar to placebo, but did not disclose detailed safety data.
Key figures behind the ALOFT-IPF readout
- Enrollment: about 1,255 adults with IPF, randomized 1:1:1 across two doses and placebo
- Primary endpoint: absolute change in forced vital capacity from baseline to Week 52
- Dose results: 60 mg statistically significant versus placebo; 120 mg not significant
- BMY shares, 12 October 2026: up more than 6% premarket, then down roughly 4%
- CTNM shares, 12 October 2026: down about 30% in morning trading
Sources: Bristol Myers Squibb, BioPharma Dive
Contineum takes the class hit without a big-pharma buffer
Contineum’s lead program, PIPE-791, is an oral LPA1 antagonist under development for IPF. It is in Phase 2 testing, BioPharma Dive indicated.
Smaller developers often trade on a larger company’s readout, as Ionis showed with its royalty upside on a Roche drug win in September 2026.
A pivotal result that complicates the LPA1 story may carry greater weight for a smaller company whose lead asset targets the same receptor.
On October 12, 2026, Contineum shares fell 35.99%, compared with a 2.60% decline for Bristol Myers Squibb at the close.
Bristol Myers carries a deeper cushion
Bristol Myers has more room to absorb a setback. The company raised its full-year 2026 revenue guidance to $49 billion to $50 billion on 30 July 2026, a transcript of its second-quarter call showed.
Big drugmakers are still racing to replace revenue before patents expire, the pressure behind Merck’s court fight over Keytruda SC in Europe.
Tolerability is the opening admilparant was built for
Marketed IPF drugs include Esbriet, Ofev and Jascayd, each with limitations, the trade outlet noted. About 1.4 million people have IPF globally, the release stated.
On Bristol Myers Squibb’s July 2026 earnings call, Chief Commercialization Officer Adam Lenkowsky said that 50% to 60% of IPF patients discontinue their medications within 12 months under current standard of care, according to the call transcript.
Uptake would also depend on US payers, where Medicare policy is moving healthcare stocks, as the court fight over Medicare’s $12.7bn star bonus pot shows.
The same day, Bristol Myers posted a positive interim Phase 3 result for RYZ-101, from its $4.1 billion RayzeBio buyout, BioPharma Dive confirmed.
What the split admilparant result means for biotech investors
Bristol Myers holds a pivotal win on paper, but the 60 mg success and 120 mg miss leave the size of the benefit undisclosed. Meeting a primary endpoint clears a statistical bar, which is a separate question from how large the effect is.
Two markers will settle the debate. The full ALOFT-IPF data arrive at a future medical meeting with no date set, and ALOFT-PPF topline results are due in early 2027.
